SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Oncoinvent reports favourable interim safety results for Radspherin in phase 2 ovarian cancer trial

Norwegian biotech company Oncoinvent ASA (OSE:ONCIN) on Tuesday reported favourable safety and toler

Related stories